CTLA4 and cancer: Immune checkpoint blockades, such as sole and dual CTLA-4 and PD-1/PD-L1 blockades, have already represented a clinical benefit for several cancers including LUAD (Skoulidis et al., 2018; de Miguel and Calvo 2020).